<DOC>
	<DOCNO>NCT00973479</DOCNO>
	<brief_summary>The purpose study evaluate clinical effectiveness safety golimumab methotrexate ( MTX ) treatment rheumatoid arthritis ( RA ) compare MTX alone .</brief_summary>
	<brief_title>An Effectiveness Safety Study Intravenous Golimumab Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) , multicenter , 2-arm ( 2 group ) study golimumab participant active RA despite concurrent MTX therapy . Approximately 564 participant randomly allocate 1 2 treatment group 2:1 ratio ie , Group 1 ( approximately 376 participant receive golimumab + MTX ) Group 2 ( approximately 188 participant receive MTX + placebo ) . Total duration study participant 112 week . Safety evaluate assessment adverse event , tuberculosis test blood testing .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis ( RA ) least 3 month prior screen Have treat tolerate methotrexate ( MTX ) dose least 15 mg/week least 3 month prior screen , stable MTX dose 15 mg/week 25 mg/week least 4 week prior screen Have active RA , define disease activity least 6 swollen 6 tender joint , time screen baseline CReactive Protein great equal 1.0 mg/dL screen No history latent active tuberculosis prior screen Other inflammatory disease , include limited psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , lyme disease Treated disease modify agent ( methotrexate ) /systemic immunosuppressive ( eg , Dpenicillamine , hydroxychloroquine , chloroquine , oral parenteral gold , sulfasalazine , leflunomide , azathioprine , cyclosporine , mycophenolate mofetil ) 4 week prior first administration study agent Received intraarticular ( joint ) , intramuscular ( muscle ) , intravenous corticosteroid , include adrenocorticotropic hormone , 4 week prior first administration study agent Known allergy human immunoglobulin proteins component golimumab Received commercial investigational antitumor necrosis factor alpha therapy exclusively infliximab , golimumab , adalimumab etanercept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Active rheumatoid arthritis</keyword>
	<keyword>Golimumab</keyword>
	<keyword>CNTO148</keyword>
	<keyword>Anti-TNFalpha monoclonal antibody</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Intravenous</keyword>
</DOC>